Wacker Biotech is your CDMO partner of choice for process development, process transfer and GMP manufacturing of vaccines, recombinant proteins, Live Biotherapeutic Products, and advanced nucleic acid therapeutics, including the full manufacturing chain from plasmid DNA (pDNA) to mRNA to lipid nanoparticle (LNP) formulation. Our expertise encompasses both conventional vaccines (live attenuated, inactivated, protein-based, conjugated polysaccharide) and next-generation mRNA vaccines. We have a 20+ year track record, manufacturing and releasing more than 650 GMP vaccine batches for clinical (phase I to III) and commercial applications.
Five state-of-the-art GMP facilities located in the U.S., Germany and The Netherlands are equipped with stainless steel fermenter vessels from 350 to 1500 liters in size as well as single-use bioreactors up to 250 liters, affording the flexibility to serve clients at R&D to commercial scale. In June 2024, we opened our state-of-the-art mRNA competence center in Halle, Germany, which effectively triples our mRNA production capacity for vaccines and advanced therapeutics.
Wacker Biotech is a wholly owned subsidiary of 110-year-old Wacker Chemie AG headquartered in Munich, Germany. At our central R&D center in Munich, scientific experts lead innovations in pDNA manufacturing, mRNA production, LNP formulation, and analytical development. For more information, visit: wacker.com/biologics.
Created by
Terrapinn is proud to be a member of isla. Working together to build sustainable events